Sinopharm Group Co (HKSE:01099) Cash-to-Debt : 0.71 (As of Dec. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Sinopharm Group Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Sinopharm Group Co's cash to debt ratio for the quarter that ended in Dec. 2024 was 0.71.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Sinopharm Group Co couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for Sinopharm Group Co's Cash-to-Debt or its related term are showing as below:

HKSE:01099' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.64 Med: 0.73 Max: 0.87
Current: 0.71

During the past 13 years, Sinopharm Group Co's highest Cash to Debt Ratio was 0.87. The lowest was 0.64. And the median was 0.73.

HKSE:01099's Cash-to-Debt is ranked worse than
54.46% of 112 companies
in the Medical Distribution industry
Industry Median: 0.88 vs HKSE:01099: 0.71

Sinopharm Group Co Cash-to-Debt Historical Data

The historical data trend for Sinopharm Group Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Sinopharm Group Co Cash-to-Debt Chart

Sinopharm Group Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

Get a 7-Day Free Trial

0.73

0.64

0.79

0.87

0.71

Sinopharm Group Co Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial															0.79	0.36	0.87	0.43	0.71

Competitive Comparison of Sinopharm Group Co's Cash-to-Debt

For the Medical Distribution subindustry, Sinopharm Group Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sinopharm Group Co's Cash-to-Debt Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Sinopharm Group Co's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Sinopharm Group Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Sinopharm Group Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	57989.025	/	(68853.769	+	12701.572)
	=	0.71

Sinopharm Group Co's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	57989.025	/	(68853.769	+	12701.572)
	=	0.71

Sinopharm Group Co (HKSE:01099) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Sinopharm Group Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Sinopharm Group Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinopharm Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (HKSE:01099) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

SHTDY:USA SHTDF:USA X2S:Germany X2S:Germany

Address

No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023

Website

http://www.sinopharmgroup.com.cn

Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.

Executives

Citic Securities Company Limited	2201 Interest of corporation controlled by you
Zhong Xin Zheng Quan Yun Fan Dan Yi Zi Chan Guan Li Ji Hua	2501 Other
Zhong Xin Zheng Quan Zi Chan Guan Li You Xian Gong Si	2102 Investment manager
Lazard Asset Management Llc	2102 Investment manager
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Citigroup Inc.	2502 Approved lending agent
Fmr Llc	2201 Interest of corporation controlled by you
Blackrock, Inc.	2201 Interest of corporation controlled by you

Sinopharm Group Co Headlines

No Headlines